99 related articles for article (PubMed ID: 8742628)
1. [Metabolism of ipriflavone].
Ferenc L; István S
Acta Pharm Hung; 1995 Nov; 65(6):215-8. PubMed ID: 8742628
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of ipriflavone].
Ferenc L; István S
Acta Pharm Hung; 1995 Nov; 65(6):219-22. PubMed ID: 8742629
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes.
Moon Y; Kim SY; Ji HY; Kim YK; Chae HJ; Chae SW; Lee HS
Xenobiotica; 2007 Mar; 37(3):246-59. PubMed ID: 17624023
[TBL] [Abstract][Full Text] [Related]
4. Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
Monostory K; Vereczkey L; Lévai F; Szatmári I
Br J Pharmacol; 1998 Feb; 123(4):605-10. PubMed ID: 9517377
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin.
Lee DY; Chung HJ; Choi YH; Lee U; Kim SH; Lee I; Lee MG
Eur J Pharm Sci; 2009 Dec; 38(5):465-71. PubMed ID: 19761842
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics and metabolism of ipriflavone in humans. I].
Vargay Z; Várkonyi P; Lévai F; Kerpel-Frónius S; Eckhardt S
Acta Pharm Hung; 1989; 59 Suppl 1():26-31. PubMed ID: 2701627
[No Abstract] [Full Text] [Related]
7. Determination of a isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography.
Kim SH; Lee JS; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):313-24. PubMed ID: 9485525
[TBL] [Abstract][Full Text] [Related]
8. The metabolism of phenylbutazone in the rat.
Bakke OM; Draffan GH; Davies DS
Xenobiotica; 1974 Apr; 4(4):237-54. PubMed ID: 4603132
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim SH; Lee MG
Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of ipriflavone (TC-80) in rats.
Yoshida K; Tsukamoto T; Torii H; Doi T; Naeshiro I; Uemura I; Tanayama S
Radioisotopes; 1985 Nov; 34(11):612-7. PubMed ID: 3834523
[TBL] [Abstract][Full Text] [Related]
11. Effects of E. Coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11.
Chung HJ; Kang HE; Bae EJ; Lee I; Kim SG; Lee MG
J Pharm Sci; 2008 Nov; 97(11):5024-36. PubMed ID: 18314883
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits.
Kim S; Lee J; Lee M
Biopharm Drug Dispos; 2000 May; 21(4):147-56. PubMed ID: 11180193
[TBL] [Abstract][Full Text] [Related]
13. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition.
Chen J; Wang S; Jia X; Bajimaya S; Lin H; Tam VH; Hu M
Drug Metab Dispos; 2005 Dec; 33(12):1777-84. PubMed ID: 16120792
[TBL] [Abstract][Full Text] [Related]
14. Disposition of ipriflavone (TC-80) in rats and dogs.
Yoshida K; Tsukamoto T; Torii H; Doi T; Naeshiro I; Shibata K; Uemura I; Tanayama S
Radioisotopes; 1985 Nov; 34(11):618-23. PubMed ID: 3834524
[TBL] [Abstract][Full Text] [Related]
15. Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
Rohatagi S; Barrett JS
Am J Ther; 1997; 4(5-6):189-98. PubMed ID: 10423610
[TBL] [Abstract][Full Text] [Related]
16. The effect of ipriflavone and its main metabolites on theophylline biotransformation.
Monostory K; Vereczkey L
Eur J Drug Metab Pharmacokinet; 1996; 21(1):61-6. PubMed ID: 8839679
[TBL] [Abstract][Full Text] [Related]
17. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats.
Chung HJ; Choi YH; Kim SH; Lee MG
J Pharm Pharmacol; 2006 Apr; 58(4):449-57. PubMed ID: 16597362
[TBL] [Abstract][Full Text] [Related]
18. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
Johnson KA; Prakash C
Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
20. Structural elucidation of hydroxylated metabolites of the isoflavan equol by gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry.
Rüfer CE; Glatt H; Kulling SE
Drug Metab Dispos; 2006 Jan; 34(1):51-60. PubMed ID: 16199471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
